1624-P: Is the Contribution of Postoperative Adult Growth Hormone Deficiency to Fatty Liver Greater Than the Contribution of Type 2 Diabetes?

Background: In recent years, adult growth hormone deficiency (AGHD) has been recognized as one of the risk factors for fatty liver. AGHD is often induced by surgery for pituitary tumors. However, there is no report comparing the contribution of AGHD and type 2 diabetes(T2D) to fatty liver in patients with both conditions following pituitary tumor surgery, so far. Therefore, this study examined the associations of AGHD and T2D with a surrogate marker of fatty liver, "ALT at 3 months post-surgery" in patients undergoing pituitary tumor surgery, using two-way analysis of variance.

Methods: The study included 69 patients who underwent surgery for pituitary tumors and underwent AGHD examination through growth hormone stimulation tests. The dependent variable was ALT at 3 months post-surgery, and independent variables were the presence of T2D (T2D group n=8, non-T2D group n=61) and the presence of AGHD (AGHD group n=23, non-AGHD group n=46).

Results and Conclusion: Both the presence of T2D and AGHD showed significant main effects (p<0.001, p=0.015, respectively), and their interaction demonstrated a significant synergistic effect (p=0.048) as well. It was demonstrated that having T2D and having AGHD both contribute to elevated ALT. However, the contribution rates to ALT were 22.0% for T2D, 5.4% for AGHD, and 3.1% for interaction. Having T2D was identified as the main contributed factor for elevated ALT. Although AGHD is recognized as a risk factor for fatty liver after pituitary tumor surgery, this study revealed that it becomes an extremely strong risk when combined with T2D.